Spontaneous hematoma in the setting of dual anti-platelet therapy with ticagrelor: A case report

Chunguang Feng1, Linguang Wang1, Lulu Wang1

  • 1Department of Cardiology, Central Hospital of Xuzhou, Xuzhou Institute of Cardiovascular Disease, Xuzhou, Jiangsu 221009, P.R. China.

Oncology Letters
|June 28, 2016
PubMed

Insights

Dual anti-platelet therapy (DAPT) with aspirin and ticagrelor may cause spontaneous hematoma in patients post-coronary stenting. This case highlights a potential risk associated with DAPT, necessitating careful patient monitoring.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • A 69-year-old male presented with right scapular pain and a palpable mass.
  • The patient had recently undergone coronary artery stenting.
  • He was on dual anti-platelet therapy (DAPT) including aspirin and ticagrelor post-procedure.

Purpose of the Study:

  • To investigate the cause of spontaneous hematoma in a patient on DAPT after coronary stenting.
  • To evaluate the potential link between DAPT and the development of spontaneous hematoma.

Main Methods:

  • Clinical presentation and patient history review.
  • Ultrasonic inspection for hematoma diagnosis.
  • Assessment of medication history, specifically DAPT.

Main Results:

  • A spontaneous hematoma was diagnosed under the right scapula via ultrasound.
  • Dual anti-platelet therapy (DAPT) with aspirin and ticagrelor was identified as the sole causative factor for the hematoma.

Conclusions:

  • Dual anti-platelet therapy (DAPT) may be associated with an increased risk of spontaneous hematoma formation.
  • Clinicians should consider DAPT as a potential cause of unexplained hematomas in patients, particularly after cardiovascular interventions.